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Summary
The effect of the synthetic glucocorticoid hormone dexamethasone
on human g chain fibrinogen gene expression was examined. The 
whole promoter region of 3.8 kb of this gene and progressive 5’-dele-
tions were inserted into a promoterless expression vector, upstream of
the luciferase gene and transiently transfected into the human hepatoma
HepG2 cells, in the presence or in the absence of dexamethasone 
stimulation. Deletion analysis allowed to identify a region located 
between –1359 and –954 bp upstream from the transcription start site,
involved in hormone inducibility. On the basis of a computer-assisted
analysis, a putative GRE was found in this region at bases –1116 to 
–1102. Specific point mutations eliminating this putative GRE led 
to complete loss of glucocorticoid inducibility, thus indicating its 
functional role. Binding of the rat glucocorticoid receptor to this site
was demonstrated by mobility-shift assays.
Introduction
Fibrinogen is a plasma glycoprotein mainly synthesized by liver 
parenchymal cells. It is secreted as a dimeric molecule, composed of
pairs of three different polypeptides, Aa, Bb and g (for review, see 1).
Fibrinogen chains are encoded by separate genes, which in humans are
clustered on chromosome 4q28 (2), organised in a g, a and b sequence
with the b gene in opposite transcriptional orientation (3). Each gene is
separately transcribed and translated and it has been demonstrated 
in different experimental systems, ranging from humans to Xenopus,
that expression of the three fibrinogen chains is a co-ordinate process,
regulated at the transcriptional level (4, 5).
Fibrinogen plays a crucial role in blood clotting process both by 
polymerisation to a fibrin network (6) and by mediating platelet 
aggregation (7). High plasma fibrinogen levels are also considered as
an independent risk factor for cardiovascular disease (for review, see 8)
and fibrinogen is considered a model protein in epidemiological studies
(9).
Fibrinogen is also involved in the acute phase response to injury and
stress (for review, see 10) and it has been suggested that circulating 
fibrinogen may be involved in regulation of the inflammatory response
(11).
The expression of a subset of hepatic proteins is regulated during the
acute phase of inflammation. The three fibrinogen genes belong to class
II acute-phase proteins regulated by glucocorticoids and interleukin-6
(IL-6) (12, 13). Most of the studies concern the induction of fibrinogen
gene expression by IL-6. IL-6 responsive elements have been identified
in a, b and g fibrinogen genes, both in humans (14-18) and in rat 
(19-21). Moreover, the molecular mechanism underlying this response
is being elucidated (20, 22).
Less information is available on the molecular analysis of glucocor-
ticoid induction of mammalian fibrinogen genes. The only data refer to
the response to glucocorticoids of the genes coding for a and b fibrinogen
chains in humans (14, 17) and for the three genes in rat (19). However,
the specific glucocorticoid response elements (GREs) have not been
precisely located and therefore no data are available on the regulation 
at the molecular level of human fibrinogen g chain expression by 
glucocorticoids.
In this paper, we describe, for the first time, the identification of a
GRE in the human g chain fibrinogen promoter. Transient expression
of constructs containing sequentially deleted 5’-flanking sequences of
the g chain gene fused to the luciferase reporter gene showed that the
promoter was inducible by the synthetic glucocorticoid dexamethasone
and allowed to identify the shortest DNA fragment (–1359 to –954 bp,
from the transcription initiation site), mediating hormone-induced 
expression. This region contains a putative GRE at bases –1116 to 
–1102. The functional relevance of this element was confirmed by 
site-directed mutagenesis and binding of the recombinant rat glucorti-
coid receptor (GR) to this site was demonstrated by electrophoretic 
mobility-shift assays.
Materials and Methods
Genomic DNA cloning. A human genomic library, inserted in the bacterio-
phage vector EMBL3 SP6/T7 (Clontech) was screened, using as probes a 
previously described 637 bp long cDNA encoding for human g chain fibrino-
gen (23) and a set of oligonucleotides. The cDNA probe encodes from amino-
acid 49 to 269 of the mature fibrinogen g chain and recognises part of the exon
III, exons IV to VII and part of exon VIII of this gene. Oligonucleotide sequen-
ces were derived from the known sequence of the human g chain fibrinogen 
gene (24).
Library screening, DNA isolation, restriction mapping, Southern blotting
and filter hybridization were performed according to standard techniques (25).
Restriction endonucleases were from New England Biolabs (Beverly, Massa-
chusetts); all the other enzymes were from Boehringer (Mannheim, Germany).
Oligonucleotides were purchased from PE-Applied Biosystems (Warring-
ton, Cheshire, United Kingdom); poly (dI-dC) was from Sigma-Aldrich GmbH
(Steinheim, Germany).
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Plasmid constructions. Plasmids containing sequential 5’-deletions of the
upstream region of the g fibrinogen gene were constructed according to the 
following strategy: the XhoI-HpaII fragment of l HF2 of about 3.8 Kb, contain-
ing the 5’-flanking region of g fibrinogen gene up to 13 bp upstream from 
the start codon, was first subcloned, after filling in of cohesive ends, into the
SmaI site of Bluescript SK(-) vector (Stratagene, San Diego, California). The
recombinant plasmid, designated as BSSK3.8, was used for sequencing and as
starting material for subsequent insertional cloning of deleted promoter regions
into the promoterless expression plasmid vector pGL2-basic, containing the 
luciferase gene of Photinus pyralis (Promega, Madison, Wisconsin). pGL2-
basic will be hereafter referred to as pGL2. To allow subsequent directional
cloning in pGL2, orientation of insertion in BSSK3.8 was analyzed by sequenc-
ing and by restriction enzyme mapping.
For subcloning the whole 5’-flanking region, BSSK3.8 was partially 
digested with EcoRI, whose site is located both in the promoter region and in
the polylinker of BSSK3.8. To generate 5’-deleted fragments, the BSSK3.8
plasmid was singly digested with the restriction enzymes EcoRI, AccI, HindIII,
or AvaII. After filling in of the cohesive ends by Klenow enzyme, each linea-
rized plasmid was digested with BamHI. Each plasmid was then destroyed by 
digestions with XbaI and KpnI. The deleted fragments were then directionally
inserted in pGL2 digested with SmaI and BglII. The boundaries of insertion of
each construct were verified by sequencing.
Plasmids were transformed into XL1-blue competent cells (Stratagene, San
Diego, California) and DNA was isolated by Qiagen-tips 500 (Qiagen GmbH,
Hilden, Germany).
DNA sequencing. DNA sequencing was carried out on both strands with a
370A automated DNA sequencer by the Dye dideoxy-terminator cycle sequenc-
ing kit with ampli-Taq FS (Applied Biosystems Division, Perkin Elmer), 
according to the manufacturer’s instructions.
Computer DNA analyses. Computer-assisted analyses of DNA sequences
were accomplished by using the software PCGene (Intelligenetics).
Cell cultures. The human hepatoma cell line HepG2 was cultured in 
Dulbecco-modified Eagle’s (DMEM) and Ham’s F12 media (1:1, vol/vol), 
supplemented with 10% foetal calf serum. HeLa cells were cultured in DMEM
containing 10% calf serum. Antibiotics (100 i.u./ml penicillin and 100 mg/ml
streptomycin) were added to the growth medium. Cells were grown in a 
humidified atmosphere of 5% CO2 and 95% air, at 37° C and cultured 
according to standard procedures.
Transfections. Transfections were performed by the calcium phosphate
technique essentially as described by Wigler et al. (26). HepG2 cells (2.5 3
106 per 10 cm-diameter dish) or HeLa cells (2 3 106 per 10 cm-diameter dish)
were plated 24 h prior to transfection. Transfection was carried out in growth
medium containing 10% charcoal-stripped foetal calf serum (Hyclone, Logan,
Utah) and CaPO4-DNA precipitate, containing 15 mg of the test plasmid and 
5 mg of the carrier plasmid (pUC18), was applied to the cells. 16 h later, this
medium was removed, cells were washed with phosphate-buffered saline (PBS)
and the medium replaced with growth medium with or without dexamethasone
(Sigma)(10–6 M). Cells were harvested for luciferase assay after 24 h.
Luciferase assays. Cells were washed twice with PBS, scraped with a 
rubber policeman in 1 ml of TEN (40 mM Tris pH 7.5, 1 mM EDTA, 150 mM
NaCl), pelleted and resuspended in 100 ml of 0.25 M Tris pH 7.8. After three 
cycles of freezing and thawing, samples were centrifuged at 4° C for 10 min 
at 5000 g. Protein content of the supernatant of each sample was determined
spectrophotometrically using the Bio-rad protein assay (München, Germany).
Amounts of supernatants, containing 100 mg of proteins, were aliquoted and 
after addition of 350 ml of a solution containing 25 mM glycylglycine pH 7.8, 
2 mM ATP pH 7.8 and 0.01 M MgSO4, tubes were placed in a Berthold 
luminometer. The reaction was initiated by the injection of 100 ml of a solution
containing 20 mM glycylglycine pH 7.8 and 0.2 mM luciferine (Sigma) and the
peak light emission, expressed as relative light units (RLU), was recorded after
30 sec.
Site-directed mutagenesis. Mutations in the GRE were produced, in the 
–1359 construct, by the Quickchange site-directed mutagenesis kit (Strata-
gene), according to the manufacturer’s instructions, using the oligonucleotide
GREm (see Fig. 3, top).
Electrophoretic mobility-shift assays. Mobility-shift assays were performed
using the purified rat glucocorticoid receptor DNA-binding domain, kindly 
provided by dr. K. Yamamoto (S. Francisco, CA). This recombinant protein
consists of aminoacids from 440 to 525 of the rat GR (27). Double-stranded
DNA fragments used in mobility-shift and competition assays were generated
by self-annealing of complementary oligonucleotides. Equimolar amounts 
of each strand were heated at 95° C and then slowly cooled down to room 
temperature. Binding reactions were carried out as described by Roberts et al.
(28); double stranded oligonucleotide probes were end labelled with T4 
polynucleotide kinase. For nucleotide sequence of probes and competitors, 
see Fig. 3, top.
In competition assays, an excess (10 to 1000 fold) of unlabelled double-
stranded competitors was preincubated in the binding reactions for 10 min. 
After the addition of the radioactive probe, the reactions were incubated for 
additional 30 min at room temperature.
Reaction mixtures were run on 5% polyacrylamide non denaturing gels in
0.53TBE (25) at 4°C at a constant voltage of 225 V. Dried gels were exposed
to Kodak (Rochester, New York) XAR5 film for one hour at –80°C with 
intensifying screens.
Results
Isolation of the 5’-flanking Region of Human Fibrinogen Gene
Out of approximately 106 plaques of a human genomic library 
screened with a human g-fibrinogen cDNA probe (23), one positive
clone, designated as lHF2 was isolated. The insert of this recombinant
phage spans about 14.2 Kb. A series of oligonucleotides, mapping 
in different regions of the gene, were synthesised on the basis of the
known sequence of fibrinogen gene (24), and used to characterise this
genomic fragment. All oligonucleotides gave a positive hybridization
signal with lHF2 insert excised from the phage vector with XhoI 
(data not shown), confirming that lHF2 contains the whole human g 
fibrinogen gene. The absence of rearrangements was checked by 
restriction enzyme analysis and hybridization with the cDNA probe.
The 5’-flanking region of this clone spanned 3799 bp. In order to
isolate this region as a whole fragment, lHF2 was double digested with
HpaII and XhoI, whose sites are located 16 bp upstream from the ATG
start codon of the g fibrinogen gene and in the polylinker of the phage
vector, respectively. The excised insert was subcloned into the Blue-
script SK(-) vector for subsequent sequencing and insertional cloning
of promoter deletions into the vector pGL2.
The promoter region was completely sequenced on both stands; 
two nucleotide differences with the previously published sequence (18)
were identified: an A instead of a G and a G instead of an A at positions
–3790 and –3725, respectively.
Identification of an Upstream Region Responsible 
for Dexamethasone Stimulation
The response of the human hepatoma HepG2 cells to glucocorticoid
stimulation, as far as the g fibrinogen gene transcription is concerned,
was verified by Northern blot analysis. After 24 h of dexamethasone
stimulation (10–6M), an increase in the level of g fibrinogen mRNA was
observed (data not shown).
In order to test whether the analyzed promoter region of g fibrino-
gen gene contained the regulatory cis-acting element/s for achieving a
dexamethasone response, the whole promoter of 3799 bp was fused to
the luciferase reporter gene into the vector pGL2. This construct was
transiently transfected into HepG2 and HeLa cells (negative control)
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and luciferase activity was assayed after 24 h in culture with or without
dexamethasone. As shown in Fig. 1, when this construct was transfect-
ed in HepG2 cells, a 2-fold increase in the expression of the reporter 
gene following hormonal induction was observed, while no hormonal
stimulation could be detected in HeLa cells. 
To determine the location of the cis-acting GRE/s within this 3.8 kb
long promoter, a set of constructs with progressive 5’-deletions were
generated. The basal and induced activities of constructs containing
3799, 2837, 1359, 954 or 373 bp of the 5’-flanking sequence fused to
the luciferase gene were tested after transfections into HepG2 cells. The
results, reported in Fig. 1, showed that the region from –1 to –954 bp
did not contain sequences responding to dexamethasone. The region
from position –954 to –1359 supported a hormonal stimulation of about 
2-fold. Hormonal induction was no further increased by sequences
from –1359 to –3799 bp. These data therefore allowed to localise the 
putative GRE/s in the g fibrinogen promoter region comprised between
position –1359 to –954.
Search for the Presence of Sequences Homologous 
to the Consensus GRE
In order to identify sequences homologous to the reported consensus
GREs, GGTACANNNTGTTCT (29) or AGAACANNNTGTTCT
(30), we performed a computer-assisted search on the 3799 bp long 
5’-flanking region of fibrinogen gene with the program Matscan 
(PcGene). The consensus GRE consists of 12 conserved nucleotides 
arranged as two hexameric half-sites, at least partially palindromic, 
separated by 3 non critical nucleotides. Since the two 15 bp long 
consensus differ in the first and third nucleotide, both consensus 
sequences were taken into account in the matrix construction. 4 puta-
tive GREs were identified by this procedure at positions –3489/–3475, 
–2809/–2795, –2634/–2620 and –1116/–1102, respectively. Only one 
of them (–1116 to –1102, TGTTCACTTTGTTAT) lies within the 
region shown to be responsible for dexamethasone inducibility on the
basis of the deletion analysis (Fig. 1) and is identical to the consensus
sequences in 9 out of 12 positions. 
Mutational Analysis of the GRE Element
To confirm functionality of this putative GRE at position –1116/
–1102, both half-sites of the GRE (Fig. 2, top) were mutated in the 
construct containing the first 1359 bp of the upstream sequence, 
Fig. 1 Identification of the region responsible for dexamethasone stimulation in the promoter of human g fibrinogen gene. A series of DNA fragments containing
progressive 5’-deletions of the human g fibrinogen promoter were cloned into the plasmid expression vector pGL2 upstream of the luciferase gene. All constructs
contained the g fibrinogen gene transcription initiation site (indicated by the bent arrow) and sequences up to position +37. Each construct was transiently trans-
fected into HepG2 cells and the construct –3799 was transfected also in HeLa cells. The transfected cells were treated with (+) or without (–) dexamethasone
(10–6M) for 24 h, before measuring luciferase activity, as described in Materials and Methods. Luciferase expression levels are expressed as percentages of the 
uninduced pGL2 vector. The fold-increase in luciferase activity by dexamethasone stimulation for each construct is indicated beside each bar. Values are the 
mean of five independent experiments for each construct, each performed in duplicate. Error bars represent the standard errors
Fig. 2 Effect of mutations in the putative GRE of human g fibrinogen promo-
ter on dexamethasone-stimulated expression. Top: Comparison of nucleotide
sequences of the wild type and mutated GREs. The putative GRE at positions 
–1116 to –1102 in the construct –1359 w. t. was mutated by site-directed muta-
genesis by replacing 4 out of 6 nucleotides in one half-site and 3 of out 6 in the
other half-site (mutated nucleotides are underlined), to produce the mutated
construct (–1359 mut). Bottom: Wild type and mutated constructs were transi-
ently transfected into HepG2 cells, as described in Materials and Methods, with
(+) or without (–) dexamethasone (10–6M). Luciferase expression levels are 
expressed as percentages of the uninduced pGL2 vector. The fold-increase in
luciferase activity by dexamethasone stimulation is indicated above each bar.
Values are the mean of two independent experiments, each performed in dupli-
cate. Error bars represent the standard errors
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generating the mutated construct –1359 mut. Wild type and mutated
constructs were transiently transfected into HepG2 cells. Upon 
dexamethasone stimulation, the wild type construct elicited the 
expected glucocorticoid response of approximately 2-fold (Fig. 2, 
bottom), whereas hormone stimulation was completely abolished in 
the construct with the mutated GRE. Basal expression driven by the 
–1359 construct containing the wild type GRE was higher than that 
driven by the –1359 mut construct.
Binding of the Recombinant Rat Glucocorticoid Receptor 
DNA-binding Domain to the Glucocorticoid Response Element
Binding of glucocorticoid receptor to the GRE identified in the 
human gfibrinogen promoter was assessed by mobility-shift assays
using a recombinant truncated rat GR, containing the DNA-binding 
domain (27). An end-labelled double-stranded synthetic oligonucleo-
tide designed as GRE and including the g fibrinogen GRE and surround-
ing nucleotides from –1131 to –1085 (Fig. 3, top), was incubated with
the purified receptor fragment and run on a non denaturing polyacryla-
mide gel. Figure 3a shows bands representing the free DNA probe (F)
and DNA occupied by one (I) or two (II) protein molecules, according
to La Baer and Yamamoto (31). The fainter band observable above
complex II (Fig. 3b, lane 2) should correspond to the complex with
three proteins (31).
The results confirmed binding of the protein to the wild type GRE
(Fig. 3a, lane 2), the stronger intensity of complex II band revealing that
dimer binding was predominant. In competition assays, only a 10003
molar excess of the same unlabelled oligonucleotide was able to 
compete off the binding (Fig. 3a, lane 5), while a perfectly palindromic
GRE resulted to compete binding already at a molar ratio of 1:100 
(Fig. 3a, lanes 8-10). A completely unrelated sequence was unable to
affect the binding of GRE to the recombinant GR (Fig 3a, lane 3).
Unexpectedly, the double-stranded oligonucleotide GREm (Fig. 3,
top), whose sequence is identical to that present in the construct –1359
mut used in transfection experiments, appeared to compete the 
DNA protein complex (Fig. 3a, lane 4), and was also able to bind the 
receptor, even if showing a fainter complex II as compared to wild type
double-stranded GRE oligonucleotide (lane 11). The affinity of GREm
for the receptor could be explained by considering that the mutagenesis
step inadvertently introduced a new GRE half-site (TGTTCG), shifted
two bases upstream from the identified GRE (Fig. 3, top). This hexamer
matches the consensus in 5 positions out of 6, including the two critical
nucleotides (32) at positions 2 and 5. 
In order to verify this hypothesis, competition assays were repeated
using a new mutated double stranded oligonucleotide (GREm2), 
in which the artificially introduced GRE half-site in GREm 
was completely mutated (Fig. 3, top). This new competitor was 
unable to affect the binding of GRE to the recombinant GR (Fig 3b, 
lane 4).
Discussion
In this paper, we report, for the first time, the identification and 
characterization of a glucocorticoid response element (GRE) in the 
human g chain fibrinogen promoter. Up to now, no GREs were charac-
terized in any mammalian fibrinogen gene.
This study was performed on a g fibrinogen promoter region of 
3799 bp. In nucleotide sequence determination of this region, two 
Fig. 3 Binding of the DNA-binding domain of rat glucocorticoid receptor (GR) to the GRE of human g fibrinogen subunit gene, evaluated by gel mobility-shift
assays. Top: Nucleotide sequences of DNA probes and of competitors used in the assays. For each DNA sequence, only the forward strand is reported. The hex-
americ half-sites of each glucocorticoid response element are boxed. Mutated nucleotides are underlined. In the GREm oligonucleotide, mutagenesis introduced a
new GRE half-site (TGTTCG) shifted two bases upstream from the wild type one. Pal GRE is an oligonucleotide containing a perfectly palindromic GRE. A) An
end-labelled double-stranded synthetic oligonucleotide, including the wild type g fibrinogen GRE and surrounding nucleotides from –1131 to –1085 (GRE probe)
or a mutated oligonucleotide containing the same mutations as in the construct –1359 mut used in transfection experiments (GREm probe), were incubated with
the purified recombinant DNA-binding domain (aminoacids 440-525) of the rat GR (38). Complexes were resolved on a non denaturing polyacrylamide gel. 
Arrows indicate the free DNA probe (F) and the DNA occupied by one (I) or two (II) protein molecules respectively. B) Electrophoretic mobility-shift assay 
performed as in A, using a different competitor, GREm2, in which also the artificially introduced GRE half-site present in GREm, was abolished
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discrepancies with the sequence reported by Mizuguchi et al. (18) were
identified. Transition at position –3790 abolishes restriction sites for
ApaI, AsuI, HaeIII and NlaIV, while transition at position -3725 does
not create nor abolish any restriction site. These nucleotide differences
could reflect a polymorphism (the genomic fragments analyzed by 
our group and by Mizuguchi et al. (18) were isolated from different 
libraries) or a sequencing artefact. Since we confirmed the absence of
HaeIII restriction site at position –3790 by restriction enzyme analysis,
we tend to favour the first hypothesis, taking also into account that 
allelic variants in the coding region of this gene have been reported
(23).
The approximate location of the GRE element was identified by
transfections of constructs containing progressively deleted 5’-flanking
sequences of the human g chain fibrinogen gene fused to the luciferase
reporter gene into the human hepatoma HepG2 cells. 
Since glucocorticoid receptor levels in some clonal lines of HepG2
can be too low for efficient stimulation of GRE-containing episomal
plasmid vectors (19), we first demonstrated by Northern blot analysis
that our HepG2 cells were a suitable cell test system for studying 
glucocorticoid stimulation of the human g fibrinogen gene. Moreover,
when a plasmid containing the whole human g fibrinogen 5’-region of
3.8 kb was transfected into these cells, an increase in the expression of
the reporter gene was observed after hormonal induction, while no 
hormonal induction could be detected after transfection of the same
construct in non hepatic cells (HeLa cells). In addition, these experi-
ments indicated the presence of regulatory cis-acting elements, i.e. of
GREs, in the g fibrinogen promoter we were analyzing.
The 2-fold increase in the expression of the reporter gene we ob-
served following hormonal induction is identical to that reported by Huber
et al. (14) for human b fibrinogen constructs and comparable to that 
observed in preliminary studies for human a fibrinogen gene (17) and
for rat fibrinogen genes (19).
Number, spacing and orientation of GREs greatly vary between 
different glucocorticoid-regulated genes (for review, see 33). This
holds true also for fibrinogen genes. In Xenopus laevis, a single GRE 
at bases –148 to –162 of the b fibrinogen gene is present (28), while 
glucocorticoid regulation of the g fibrinogen gene requires at least three
nearby GREs and an accessory factor binding site, all within the 
first 187 bp of the promoter (34). In the human g fibrinogen gene, 
we have shown that a GRE at position –1116 to –1102 confers dex-
amethasone inducibility. In human a and b fibrinogen genes, hormone
responsiveness has been located in the first 217 bp of the 5’-flanking 
sequence (17) and in a fairly large region between –2900 and –1503
(14), respectively. Rat a and g subunit genes have been shown to 
contain glucocorticoid-responsive sequences within 600 and 800 bp 
of the promoter, respectively, while in rat b gene, hormone inducibility
was conferred by a fragment from position –349 to –193 (19). How-
ever, the GRE elements of these mammalian fibrinogen genes were 
no further analyzed in detail and their exact location was not estab-
lished.
Like other characterised GREs, which do not match the consensus
sequences at all positions (28, 34-39), the human g fibrinogen GRE
shows three mismatches with the consensus GRE reported by Beato
(29) and four mismatches with that reported by Faisst and Meyer (30).
Three out of four bases which has been demonstrated to be most 
critical for glucocorticoid receptor binding, at least in the distal GRE of
rat TAT gene (32) are conserved also in the human g fibrinogen GRE
(positions 2, 5, 11), while position 14 is an A instead of a C. In this 
respect it should be noted that, also in other characterised GREs, these
four critical nucleotides are not strictly conserved (35, 37).
In addition to deletion analysis, the functional significance of the 
human g fibrinogen GRE at position –1116/–1102 was confirmed by 
site-directed mutagenesis and electrophoretic mobility-shift assays. 
Mutations within both half-sites of the GRE element completely
abolished glucocorticoid responsiveness of a g fibrinogen-luciferase
plasmid construct containing 1359 bp of the upstream sequence. 
Even if mutagenesis inadvertently introduced a new GRE half-site
(TGTTCG) shifted two bases upstream from the wild type GRE half-
site (Fig. 3, top), the presence of a single GRE half-site was unable to
sustain hormone induction, in agreement with the observations reported
by Raju et al. (36) and Argenton et al. (40). No evidence for an over-
lapping binding site for an accessory transcription factor reported by
Woodward et al. (34) in Xenopus g fibrinogen gene was detected by a
computer assisted search.
In mutational analysis experiments, a variation in the level of basal
expression of constructs containing the mutagenised GRE was ob-
served by our and other groups (34, 36, 41). This finding doesn’t seem
to be restricted to the GRE elements, since for instance mutations in the
IL-6 responsive elements of fibrinogen genes led to a reduction in 
the basal level of the mutagenized constructs in transfected cells 
(16, 17, 21). According to Butz and Hoppe-Seyler (41), this variation
can be explained by supposing that mutations in these critical DNA 
sequences would inactivate other possible regulatory cis-acting 
elements involved in mediating induction of gene expression, as also
suggested by the decrease in basal expression of the construct contain-
ing the deletion of this region (–1359 to –954, see Fig. 1). In this 
respect, one of us (S.D.) noticed that one of the consensus sequences for
the liver-enriched transcription factor HNF-3 (42) overlaps the human
g fibrinogen GRE site. At position –1116/–1106, a sequence matching
the HNF-3 consensus in 9 nucleotides out of 11 is present. It is 
interesting to note that it has been recently reported that HNF-3 acts as
a tissue-specific accessory factor in supporting glucocorticoid-induced
transcription of other genes such as those coding for phosphopyruvate
carboxykinase, insulin-like growth factor-binding protein 1 (43, 44)
and tyrosine aminotransferase (45). The possible role of HNF-3 
proteins in the regulation of glucocorticoid-induced expression of the
human g fibrinogen subunit remains to be clarified. This would 
increase our understanding of how induction of g fibrinogen gene is 
regulated by glucocorticoids.
Mobility-shift assays showed that a protein-DNA complex is formed
by the g fibrinogen GRE with the DNA-binding domain of the rat GR, 
indicating that this GRE physically interacts with the GR. The observa-
tion that binding affinity of the g fibrinogen GRE was approximately
10 fold lower than that of a perfectly palindromic GRE is concordant
with the data of Roberts et al. (28) for Xenopus b fibrinogen GRE. The
mutated double-stranded GRE oligonucleotide (GREm) was also able
to bind the GR and to compete off the binding of the wild type GRE 
to the GR. This unexpected finding could be due to the presence of a
new GRE half-site introduced during mutagenesis (Fig. 3, top). In 
agreement with this conclusion is the observation that in the binding of
the GR to GREm, the monomeric complex is predominant. Involve-
ment of this artificially introduced GRE half-site in the competition
with the binding to GR was demonstrated by a further mutagenesis 
step. Removal of this half-site by means of nucleotide substitutions,
leading to GREm2 oligonucleotide, completely abolished the ability to
compete off the binding of GR to GRE.
The identification of a specific GRE in the promoter of the human g
fibrinogen gene offers the first “building block” for the elucidation 
of the molecular mechanism underlying the increase in plasmatic 
fibrinogen levels in the acute phase response to injury and stress.
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Vitamin K Deficiency Bleeding (VKDB) in infancy has
a high incidence of intracranial bleeding. Vitamin K
given intramusculary at birth is the most effective 
way of prophylaxis, but since it was suspected to 
increase the risk of childhood cancer it was replaced
in many countries by oral Vitamine K with conse-
quent increase in VKDB. To solve this dilemma inter-
nationally renowned experts presented their contro-
versial standpoints. The facts reported serve as base
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